Hematopoietic cell transplantation, Version 2.2020

Ayman Saad; Marcos de Lima; Sarah Anand; Vijaya Raj Bhatt; Ryan Bookout; George Chen; Daniel Couriel; Antonio Di Stasi; Areej El-Jawahri; Sergio Giralt; Jonathan Gutman; Vincent Ho; Mitchell Horwitz; Joe Hsu; Mark Juckett; Mohamed Kharfan Dabaja; Alison W. Loren; Javier Meade; Marco Mielcarek; Jonathan Moreira; Ryotaro Nakamura; Yago Nieto; Julianna Roddy; Gowri Satyanarayana; Mark Schroeder; Carlyn Rose Tan; Dimitrios Tzachanis; Jennifer L. Burns; Lenora A. Pluchino

doi:10.6004/jnccn.2020.0021

Hematopoietic cell transplantation, Version 2.2020

Ayman Saad, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Sergio Giralt, Jonathan Gutman, Vincent Ho, Mitchell Horwitz, Joe Hsu, Mark Juckett, Mohamed Kharfan Dabaja, Alison W. Loren, Javier Meade, Marco Mielcarek, Jonathan MoreiraRyotaro Nakamura, Yago Nieto, Julianna Roddy, Gowri Satyanarayana, Mark Schroeder, Carlyn Rose Tan, Dimitrios Tzachanis, Jennifer L. Burns, Lenora A. Pluchino

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.

Original language	English (US)
Pages (from-to)	599-634
Number of pages	36
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2020.0021
State	Published - May 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2020.0021

Cite this

Saad, A., de Lima, M., Anand, S., Bhatt, V. R., Bookout, R., Chen, G., Couriel, D., Di Stasi, A., El-Jawahri, A., Giralt, S., Gutman, J., Ho, V., Horwitz, M., Hsu, J., Juckett, M., Dabaja, M. K., Loren, A. W., Meade, J., Mielcarek, M., ... Pluchino, L. A. (2020). Hematopoietic cell transplantation, Version 2.2020. JNCCN Journal of the National Comprehensive Cancer Network, 18(5), 599-634. https://doi.org/10.6004/jnccn.2020.0021

Saad, A, de Lima, M, Anand, S, Bhatt, VR, Bookout, R, Chen, G, Couriel, D, Di Stasi, A, El-Jawahri, A, Giralt, S, Gutman, J, Ho, V, Horwitz, M, Hsu, J, Juckett, M, Dabaja, MK, Loren, AW, Meade, J, Mielcarek, M, Moreira, J, Nakamura, R, Nieto, Y, Roddy, J, Satyanarayana, G, Schroeder, M, Tan, CR, Tzachanis, D, Burns, JL & Pluchino, LA 2020, 'Hematopoietic cell transplantation, Version 2.2020', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 5, pp. 599-634. https://doi.org/10.6004/jnccn.2020.0021

@article{481e3eb1ccbb4129a7bd2db72bde35a6,

title = "Hematopoietic cell transplantation, Version 2.2020",

abstract = "Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient{\textquoteright}s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.",

author = "Ayman Saad and {de Lima}, Marcos and Sarah Anand and Bhatt, {Vijaya Raj} and Ryan Bookout and George Chen and Daniel Couriel and {Di Stasi}, Antonio and Areej El-Jawahri and Sergio Giralt and Jonathan Gutman and Vincent Ho and Mitchell Horwitz and Joe Hsu and Mark Juckett and Dabaja, {Mohamed Kharfan} and Loren, {Alison W.} and Javier Meade and Marco Mielcarek and Jonathan Moreira and Ryotaro Nakamura and Yago Nieto and Julianna Roddy and Gowri Satyanarayana and Mark Schroeder and Tan, {Carlyn Rose} and Dimitrios Tzachanis and Burns, {Jennifer L.} and Pluchino, {Lenora A.}",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",

year = "2020",

month = may,

doi = "10.6004/jnccn.2020.0021",

language = "English (US)",

volume = "18",

pages = "599--634",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

TY - JOUR

T1 - Hematopoietic cell transplantation, Version 2.2020

AU - Saad, Ayman

AU - de Lima, Marcos

AU - Anand, Sarah

AU - Bhatt, Vijaya Raj

AU - Bookout, Ryan

AU - Chen, George

AU - Couriel, Daniel

AU - Di Stasi, Antonio

AU - El-Jawahri, Areej

AU - Giralt, Sergio

AU - Gutman, Jonathan

AU - Ho, Vincent

AU - Horwitz, Mitchell

AU - Hsu, Joe

AU - Juckett, Mark

AU - Dabaja, Mohamed Kharfan

AU - Loren, Alison W.

AU - Meade, Javier

AU - Mielcarek, Marco

AU - Moreira, Jonathan

AU - Nakamura, Ryotaro

AU - Nieto, Yago

AU - Roddy, Julianna

AU - Satyanarayana, Gowri

AU - Schroeder, Mark

AU - Tan, Carlyn Rose

AU - Tzachanis, Dimitrios

AU - Burns, Jennifer L.

AU - Pluchino, Lenora A.

N1 - Publisher Copyright: © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

PY - 2020/5

Y1 - 2020/5

N2 - Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.

AB - Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.

UR - http://www.scopus.com/inward/record.url?scp=85086354435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086354435&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0021

DO - 10.6004/jnccn.2020.0021

M3 - Article

C2 - 32519831

AN - SCOPUS:85086354435

SN - 1540-1405

VL - 18

SP - 599

EP - 634

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Hematopoietic cell transplantation, Version 2.2020

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this